AusBiotech launches report on C&G manufacturing opportunities

Life sciences industry body AusBiotech has launched its National Cell and Gene Manufacturing Blueprint, which it says offers a unified and collaborative approach to expanding a sovereign cell and gene industry in Australia.

According to AusBiotech, which commissioned the report, the local biotechnology sector-led effort provides recommendations on how the nation’s ecosystem can develop the required workforce, expertise and infrastructure, to enable regional leadership and delivery of a new generation of medical treatments.

Lorraine Chiroiu, AusBiotech’s CEO said in a statement on Thursday that, “This report is an opportunity to harness Australia’s role in the global cell and gene ecosystem, and to ensure that we are best-placed as a nation to be involved in and benefit from these life-changing therapeutic approaches now and into the future. 

“In order to secure Australia’s position as a critical hub for cell and gene manufacturing, timely Government support and funding is essential to fully realising opportunity lying in front of us.”

 The statement describes “C&G” products as a new frontier in medicine, with demonstrated life-saving and life-changing results for patients with rare diseases and cancer and promise in addressing more common conditions. 

Jenny Herz, co-founder of Biointelect – which partnered with AusBiotech on developing the strategy – said Australia possessed “a unique opportunity to leverage our local strengths in research and clinical trials, improve access for Australian patients and drive the growth of an export industry.”

The report makes 11 key recommendations and addresses key areas outlined in the earlier Strategic Roadmap for the Regenerative Medicine Sector around skills development, investment opportunities, collaboration and capability across the value chain, and clear market access pathways aligned with leading global markets.

It can be read here.

Picture: credit www.celltherapies.com.au

Further reading

Regenerative medicine manufacture expanding in Australia: AusBiotech

New regenerative medicine reports detail current capability, capacity and clinical trials, future potential